All press releases
People
7 May 2026
Man & Science appoints Prof. Jean-Pierre Van Buyten as Chief Medical Officer
Co-founder and internationally recognised neuromodulation specialist to lead the company’s clinical strategy
LIÈGE, Belgium — 7 May 2026 — Man & Science SA, a privately held medical device company developing neuromodulation therapies for severe headache disorders, today announced the appointment of Prof. Jean-Pierre Van Buyten as Chief Medical Officer.
Prof. Van Buyten is a leading authority in neuromodulation and pain medicine, with more than 80 peer-reviewed publications and over 4,800 academic citations. Since 2004 he has headed the Multidisciplinary Pain Management Centre at VITAZ in Sint-Niklaas, Belgium. His clinical work there has focused on invasive neuromodulation, including spinal cord stimulation, peripheral nerve stimulation, and neurostimulation for refractory headache and facial pain. A co-founder of Man & Science and its Principal Scientist since the company’s inception, Prof. Van Buyten now takes on the formal role of Chief Medical Officer, leading the company’s clinical strategy.
The appointment comes as Man & Science advances the clinical study of its occipital nerve stimulation (ONS) system and continues development of its injectable stimulation platform.
“We are delighted to welcome Prof. Jean-Pierre Van Buyten as Chief Medical Officer. Jean-Pierre brings an exceptional combination of scientific credibility, clinical expertise and strategic insight in neuromodulation and headache medicine. His experience will be invaluable as we advance our ONS clinical programme, develop our injectable neurostimulation platform, and build a company focused on patients with severe headache disorders.”
— Hugues Wallemacq, Chief Executive Officer
Prof. Van Buyten has held numerous leadership positions in pain management and neuromodulation, and has contributed extensively to clinical research, scientific publications and international education. He is a founding member of the Benelux Chapter of the International Neuromodulation Society. He also chairs the board of European Continuing Medical Training (ECMT), a non-profit organisation that coordinates more than 40 meetings and workshops a year across the EU on neuromodulation education. He speaks regularly at international congresses, often on neurostimulation for head and facial pain, the indication at the heart of Man & Science’s ONS programme.
“Man & Science is developing highly innovative solutions in areas where patients continue to face major unmet needs. I am excited to take on this role at an important stage and to work with the team to advance both the ONS programme and the injectable platform. I believe these technologies have the potential to improve access to minimally invasive neuromodulation and to bring meaningful benefits to patients.”
— Prof. Jean-Pierre Van Buyten, Chief Medical Officer
“Jean-Pierre is one of the most respected figures in neuromodulation worldwide. His deep expertise in neurostimulation, headache disorders and clinical development will play a critical role as the company executes its strategy.”
— Robert Taub, Chairman of the Board
About Man & Science
Man & Science SA is a privately owned, clinical-stage medical device company based in Liège, Belgium. The company develops next-generation, minimally invasive neuromodulation technologies for the treatment of chronic and debilitating neurological disorders. Its programmes include the ONFIELD pilot clinical study, which is evaluating a miniaturised occipital nerve stimulation (ONS) implant in patients with chronic, refractory cluster headache, as well as an injectable peripheral nerve stimulation (iPNS) platform designed to shift neuromodulation from surgery to injection and expand access to neuromodulation for patients with severe migraine and other neurological disorders.
Media contact
Hugues Wallemacq, Chief Executive Officer, hugues.wallemaq@manandscience.com
Forward-looking statements. This press release may contain forward-looking statements about clinical development, regulatory plans and future activities. These are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Man & Science undertakes no obligation to update them.
CAUTION: Investigational devices. The ONSS and iSPGS systems are investigational devices and are not approved or cleared for commercial use in any market. In the United States: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use. In the European Union: Exclusively for clinical investigation under Regulation (EU) 2017/745 (MDR). FDA Breakthrough Device Designation does not constitute FDA clearance, approval, or marketing authorization.
Newsroom
More press releases.
All press releases